Pediatrix Medical Group, Inc. (NYSE:MD) EVP Mary Ann E. Moore Sells 8,108 Shares

Pediatrix Medical Group, Inc. (NYSE:MD) EVP Mary Ann E. Moore sold 8,108 shares of the business’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $16.00, for a total transaction of $129,728.00. Following the completion of the sale, the executive vice president now directly owns 135,810 shares of the company’s stock, valued at approximately $2,172,960. The trade was a 5.63 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Pediatrix Medical Group Trading Down 3.2 %

Shares of MD opened at $14.74 on Friday. The company has a current ratio of 1.42, a quick ratio of 1.42 and a debt-to-equity ratio of 0.83. Pediatrix Medical Group, Inc. has a 52-week low of $6.62 and a 52-week high of $16.41. The business’s fifty day moving average is $12.46 and its 200-day moving average is $9.81.

Pediatrix Medical Group (NYSE:MD) last released its earnings results on Friday, November 1st. The company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.07. The firm had revenue of $511.20 million for the quarter, compared to analysts’ expectations of $498.87 million. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The business’s revenue for the quarter was up .9% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.29 earnings per share. As a group, analysts forecast that Pediatrix Medical Group, Inc. will post 1.25 earnings per share for the current year.

Hedge Funds Weigh In On Pediatrix Medical Group

A number of institutional investors have recently added to or reduced their stakes in MD. Quest Partners LLC grew its holdings in Pediatrix Medical Group by 25.6% during the 3rd quarter. Quest Partners LLC now owns 3,054 shares of the company’s stock worth $35,000 after acquiring an additional 622 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Pediatrix Medical Group by 3.5% during the second quarter. The Manufacturers Life Insurance Company now owns 32,387 shares of the company’s stock worth $245,000 after buying an additional 1,088 shares during the period. ProShare Advisors LLC raised its stake in Pediatrix Medical Group by 7.4% during the first quarter. ProShare Advisors LLC now owns 16,937 shares of the company’s stock worth $170,000 after buying an additional 1,167 shares during the last quarter. Nisa Investment Advisors LLC lifted its holdings in Pediatrix Medical Group by 47.2% in the second quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company’s stock valued at $36,000 after buying an additional 1,524 shares during the period. Finally, SummerHaven Investment Management LLC boosted its position in Pediatrix Medical Group by 3.8% during the second quarter. SummerHaven Investment Management LLC now owns 55,951 shares of the company’s stock valued at $422,000 after acquiring an additional 2,069 shares during the last quarter. 97.71% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have issued reports on MD. StockNews.com raised shares of Pediatrix Medical Group from a “hold” rating to a “buy” rating in a report on Wednesday. Truist Financial boosted their price target on Pediatrix Medical Group from $13.00 to $16.00 and gave the company a “hold” rating in a research note on Monday, November 4th. UBS Group raised their price objective on Pediatrix Medical Group from $10.50 to $16.50 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Mizuho upped their target price on Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a research report on Monday, November 4th. Finally, Deutsche Bank Aktiengesellschaft raised their price target on Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a “hold” rating in a research report on Monday, November 4th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat, Pediatrix Medical Group has a consensus rating of “Hold” and an average target price of $16.10.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.